Advertisement
Journal Home
Search for

Volume 24, Issue 1, Pages 61-79 (February 2010)


View previous. 8 of 15 View next.

Gynaecologic cancer complicating pregnancy: An overview

Frédéric Amant, MD, PhD (Professor Gynaecological Oncology)aCorresponding Author Informationemail address, Lieselot Brepoels, MD, PhD (Trainee Nuclear Medicine)b, Michael J. Halaska, MD, PhD (Gynaecological Oncologist)c, Mina Mhallem Gziri, MD (Gynaecologist)d, Kristel Van Calsteren, MD (Research Fellow Gynaecological Oncology)a

published online 25 August 2009.

Cancer complicating pregnancy endangers two lives. Any approach should look at both maternal and foetal safety. Maternal prognosis will not improve by terminating the pregnancy. Imaging for staging purposes is possible, and sonar and magnetic resonance imaging are the preferred examinations. Abdominopelvic computed tomography exposes the foetus to the highest doses radiation and should be avoided.

Provided a thorough maternal monitoring to ensure a stable uteroplacental blood flow and foetal oxygenation, surgical techniques that are used in non-pregnant patients are also safe for pregnant patients. Radiotherapy of the upper part of the body is possible during pregnancy, but during the third trimester the close distance may put the foetus at risk. Chemotherapy during the second or third trimester can be administered without increasing the incidence of congenital malformations. A systematic analysis, especially on the long-term outcome of the offspring after cancer treatment during pregnancy is still lacking.

Here, we present a summary of issues related to the diagnosis and treatment of gynaecological malignancies during pregnancy. Firstly, we describe general diagnostic and cancer-treatment-related problems. In the second part, organ pathology including breast, cervical, ovarian, endometrial and vulvar cancer is discussed.

a Obstetrics and Gynaecology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium

b Nuclear Medicine, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium

c Obstetrics and Gynaecology, Charles University in Prague, 2nd Medical Faculty, Czech Republic

d Obstetrics and Gynaecology, Université Catholique de Louvain, Belgium

Corresponding Author InformationCorresponding author. Tel.: +32 16 34 42 52; Fax: +32 16 34 46 29.

 Frédéric Amant is clinical researcher for F.W.O.; Kristel Van Calsteren is aspirant for F.W.O.; This work is supported by F.W.O. Project G. 0358.06, ‘Stichting tegen kanker Project SCIE2006-17’, Research Fund K.U.Leuven.

PII: S1521-6934(09)00102-3

doi:10.1016/j.bpobgyn.2009.08.001


View previous. 8 of 15 View next.

Advertisement